<DOC>
	<DOCNO>NCT02582658</DOCNO>
	<brief_summary>The study seek provide evidence effectiveness obtain patient report outcome ( PRO ) work productivity data interferon-free ABBVIE REGIMEN +/- Ribavirin ( RBV ) chronic hepatitis C virus infect participant Austria .</brief_summary>
	<brief_title>Paritaprevir/r - Ombitasvir , ± Dasabuvir , ± Ribavirin Patients With Chronic Hepatitis C - An Observational Study Austria ( REAL )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Treatmentnaïve experience adult male female patient confirm chronic hepatitis C , genotype 1 4 , receive combination therapy interferonfree ABBVIE REGIMEN ± Ribavirin ( RBV ) accord standard care line current local label If RBV coadministered ABBVIE REGIMEN , prescribe line current local label ( special attention contraception requirement contraindication pregnancy ) Patients must voluntarily sign date patient authorization use disclose his/her anonymized health data prior inclusion study Patient must participate intend participate concurrent interventional therapeutic trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Paritaprevir</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Ombitasvir</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV</keyword>
</DOC>